Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-Current Assets (2016 - 2025)

UroGen Pharma (URGN) has disclosed Non-Current Assets for 10 consecutive years, with $14.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 50.7% year-over-year to $14.4 million, compared with a TTM value of $53.2 million through Dec 2025, up 130.22%, and an annual FY2025 reading of $14.4 million, up 50.7% over the prior year.
  • Non-Current Assets was $14.4 million for Q4 2025 at UroGen Pharma, down from $16.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $17.0 million in Q1 2023 and bottomed at $2.9 million in Q2 2024.
  • Average Non-Current Assets over 5 years is $9.3 million, with a median of $9.3 million recorded in 2021.
  • The sharpest move saw Non-Current Assets plummeted 90.39% in 2021, then skyrocketed 311.28% in 2025.
  • Year by year, Non-Current Assets stood at $5.4 million in 2021, then grew by 25.32% to $6.7 million in 2022, then skyrocketed by 35.95% to $9.1 million in 2023, then rose by 4.94% to $9.6 million in 2024, then skyrocketed by 50.7% to $14.4 million in 2025.
  • Business Quant data shows Non-Current Assets for URGN at $14.4 million in Q4 2025, $16.5 million in Q3 2025, and $11.8 million in Q2 2025.